Single dose Nexium [esomeprazole] 40mg qam vs lansoprazole 30mg bid for control of symptomatic GERD [gastro-oesophageal reflux] - a double-blind cross-over study

Trial Profile

Single dose Nexium [esomeprazole] 40mg qam vs lansoprazole 30mg bid for control of symptomatic GERD [gastro-oesophageal reflux] - a double-blind cross-over study

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2009

At a glance

  • Drugs Esomeprazole; Lansoprazole
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2009 Planned number of patients added to 50 as reported by ClinicalTrials.gov.
    • 24 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top